Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Lynk's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that the Phase II clinical trial of LNK01001 […]
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat […]
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]
Health Canada Accepts New Drug Submission for lecanemab as Treatment for Early Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that Health Canada has accepted a New Drug Submission […]
Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
Sony Corporation and Astellas Pharma today announced that they have entered into a collaborative research […]
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
Exscientia today announced that Sumitomo Pharma plans to initiate a Phase 1 clinical study of […]
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
Personalis, the National Cancer Center, and Ono Pharmaceutical today announced they have entered into a […]
Malaysian Genomics Inks Expansion Agreement in Bangladesh
Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced a strategic […]
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced the completion of […]
Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases
Nido Biosciences, a clinical-stage company developing precision treatments for debilitating neurological diseases, emerged from stealth […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more